The following drugs will require PA effective February 1, 2026
| RX | Generic | HCPCS Code | Product | Effective Date |
|---|---|---|---|---|
| Exdensur | Depemokimab-ULAA Subcutaneous Soln | J3590 | Commercial | 2/1/2026 |
| Ryvrevant Faspro | Amivantamab-hyaluronidase-LPUJ Inj | J9999 | Commercial | 2/1/2026 |
| Vabrinty | Leuprolide Acetate Subcutaneous Inj Kit | J9217 | Medicare and Commercial | 2/1/2026 |
| Yartemleya | Narsoplimab-WUUG IV Soln | J3490, J3590 | Commercial | 2/1/2026 |